Toggle Main Menu Toggle Search

Open Access padlockePrints

Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge

Lookup NU author(s): Dr Brian FordORCiD, Dr Shruti Chachra, Ahmed Alshawi, Alfie Brennan, Dr Suzannah HarnorORCiD, Dr Celine CanoORCiD, Professor Loranne Agius



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.Aim: To test the hypothesis that glucokinase activators (GKAs) induce hepatic adaptations that alter intra-hepatocyte metabolite homeostasis. Methods: C57BL/6 mice on a standard rodent diet were treated with a GKA (AZD1656) acutely or chronically. Hepatocytes were isolated from the mice after 4 or 8 weeks of treatment for analysis of cellular metabolites and gene expression in response to substrate challenge. Results: Acute exposure of mice to AZD1656 or a liver-selective GKA (PF-04991532), before a glucose tolerance test, or challenge of mouse hepatocytes with GKAs ex vivo induced various Carbohydrate response element binding protein (ChREBP) target genes, including Carbohydrate response element binding protein beta isoform (ChREBP-β), Gckr and G6pc. Both glucokinase activation and ChREBP target gene induction by PF-04991532 were dependent on the chirality of the molecule, confirming a mechanism linked to glucokinase activation. Hepatocytes from mice treated with AZD1656 for 4 or 8 weeks had lower basal glucose 6-phosphate levels and improved ATP homeostasis during high substrate challenge. They also had raised basal ChREBP-β mRNA and AMPK-α mRNA (Prkaa1, Prkaa2) and progressively attenuated substrate induction of some ChREBP target genes and Prkaa1 and Prkaa2. Conclusions: Chronic GKA treatment of C57BL/6 mice for 8 weeks activates liver ChREBP and improves the resilience of hepatocytes to compromised ATP homeostasis during high-substrate challenge. These changes are associated with raised mRNA levels of ChREBP-β and both catalytic subunits of AMP-activated protein kinase.

Publication metadata

Author(s): Ford BE, Chachra SS, Alshawi A, Brennan A, Harnor S, Cano C, Baker DJ, Smith DM, Fairclough RJ, Agius L

Publication type: Article

Publication status: Published

Journal: Diabetes, Obesity and Metabolism

Year: 2020

Volume: 22

Issue: 11

Pages: 1985-1994

Print publication date: 01/11/2020

Online publication date: 10/06/2020

Acceptance date: 07/06/2020

Date deposited: 22/10/2020

ISSN (print): 1462-8902

ISSN (electronic): 1463-1326

Publisher: Blackwell Publishing Ltd


DOI: 10.1111/dom.14111

PubMed id: 32519798


Altmetrics provided by Altmetric


Funder referenceFunder name
MR/P002854/1Medical Research Council (MRC)